Journal article
Pertuzumab: new hope for patients with HER2-positive breast cancer
M Capelan, L Pugliano, E De Azambuja, I Bozovic, KS Saini, C Sotiriou, S Loi, MJ Piccart-Gebhart
ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2013
Abstract
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) overexpression is detected in approximately 15% to 20% of all breast cancers (BCs). A revolutionary change in the prognosis of this subgroup of patients has occurred since trastuzumab therapy was introduced into daily clinical practice. However, because trastuzumab resistance is common, new molecules with complementary and/or synergistic mechanisms of action have been developed. Pertuzumab is a new anti-HER2 humanized monoclonal antibody that prevents the formation of HER2 dimers. MATERIAL AND METHODS: A computer-based literature search was carried out using PubMed (keywords: breast neoplasm, dimerization, HER-2, pertuzumab); data r..
View full abstractGrants
Funding Acknowledgements
EdeA has declared honoraria and travel grant from Roche, and MJP-G has also declared honoraria and consultancy from Roche.